Careers  |  Sign In  |  Register

Genetic Mutation Predicts Responses to Immunotherapy in Melanoma


With the growth of immunotherapies in recent years as an effective melanoma treatment option, there are still patients who do not respond well to immunotherapies. Hildur Helgadottir, MD, PhD, of the Department of Oncology Pathology, Karolinska Institutet and Karolinska University Hospital Solna in Stockholm, Sweden, and colleagues, concluded that increased knowledge about genetic mutations in patients will continue to better inform treatment options and outcomes. Patients with the CDKN2A gene mutation, for example, have been observed to have poorer melanoma-specific survival outcomes.

Learn more by clicking here.